A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer  by Lu, Shun et al.
206 Journal of Thoracic Oncology ®  •  Volume 10, Number 1, January 2015
Background: Based on promising efficacy in a single-arm study, a 
randomized phase II trial was designed to compare the efficacy and 
safety of adding rh-endostatin (Endostar) to first-line standard etopo-
side and carboplatin (EC) chemotherapy for treatment of extensive-
stage small-cell lung cancer.
Methods: One hundred forty Chinese patients with pathologically 
confirmed, extensive-stage small-cell lung cancer were randomly 
assigned to EC alone or rh-endostatin + EC for 4–6 cycles, followed 
by single-agent rh-endostatin until progression or unacceptable tox-
icity. The primary endpoint was progression-free survival (PFS). The 
secondary endpoints included overall survival, Objective response 
rate (ORR), and quality of life.
Results: Median PFS was 6.4 months with rh-endostatin + EC 
(n = 69) and 5.9 months with EC (n = 69) (hazard ratio 0.8 [95% 
confidence interval 0.6–1.1]). PFS was significantly higher with rh-
endostatin + EC than with EC (hazard ratio 0.4 [0.2–0.9; p = 0.020]) 
in female. Median overall survival was similar in both groups (12.1 
versus 12.4 months, respectively [p = 0.82]). ORR was higher in the 
rh-endostatin + EC group (75.4%) than in the EC group (66.7%) 
(p = 0.348). The efficacy of rh-endostatin + EC relative to that of EC 
was reflected by greater improvements in patient-assessed quality of 
life scores after 4 and 6 weeks of treatment. There was no difference 
between each regimen in the incidence of nonhematological or Grade 
III–IV hematological toxicities.
Conclusions: Addition of rh-endostatin to EC for the treatment of 
extensive-stage small-cell lung cancer had an acceptable toxicity pro-
file, but did not improve overall survival, PFS, and ORR.
Key Words: Etoposide, Carboplatin, Rh-endostatin, Extensive-stage 
small-cell lung cancer, Survival.
(J Thorac Oncol. 2015;10: 206–211)
Chemotherapy with etoposide and cisplatin or carbopla-tin has been the standard treatment for small-cell lung 
cancer (SCLC) over the last 30 years. These regimens are 
associated with response rates of 50–60% with a very short 
median progression-free survival (PFS) of 2–6 months and 
median survival times of 7–11 months.1,2 Rh-endostatin 
(Endostar) is a novel recombinant human endostatin, and 
was approved for non–SCLC (NSCLC) in China in 2005. It 
has been shown to improve overall survival (OS) and PFS 
when combined with first line chemotherapy in patients with 
advanced NSCLC.3,4 A single-arm phase II study of cisplatin/
etoposide plus Rh-endostatin in 33 patients with extensive-
stage SCLC reported a median PFS of 5 months, median OS 
of 11.5 months, and objective response rate (ORR) of 69.7%.5 
This study aimed to assess the efficacy and safety of rh-end-
ostatin in combination with first-line standard chemotherapy 
of etoposide plus carboplatin in the treatment of extensive-
stage SCLC.
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MATERIAL AND METHODS
Patients and Eligibility
This study enrolled 140 patients with histologically or 
cytologically confirmed extensive-stage, treatment-naive SCLC 
at 14 medical institutions in China between July 2009 and Aug 
2011. All patients were between 18 and 75 years with an Eastern 
Cooperative Oncology Group (ECOG) performance status score 
of 0 to 2 and expected survival of more than 12 weeks. Other 
inclusion/exclusion/withdrawal criteria were standard for phase 
II studies (see Supplemental Digital Content, http://links.lww.
com/JTO/A700). Details on informed consent, ethical clear-
ance, and trial registration are also provided in the Supplemental 
Digital Content (http://links.lww.com/JTO/A700).
Study Design
Patients were randomly assigned to the following two 
treatment groups: etoposide and carboplatin (EC) group, 
and EC + rh-endostatin group. The EC + rh-endostatin 
group received a 3- to 4-hour intravenous infusion of rh-
endostatin (7.5 mg/m2 once daily, equivalent to 1.2 × 105 U/
m2 of human endostatin; Shandong Simcere-Medgenn Bio-
Pharmaceutical Co., Ltd., Yantai, China) on Days 1 to 14 of 
each 21-day cycle. Etoposide was administered (60 mg/m2, 
Qilu Pharmaceutical Co., Ltd., Jinan, China) on days 1 to 
5, and carboplatin (Bristol-Myers Squibb S.r.I., Sermoneta, 
Italy) was administered at a target area under the concentra-
tion curve of 5 mg/ml/min on day 1 of each cycle. All patients 
received four to six 21-day cycles. After four to six cycles, 
patients who did not display disease progression continued to 
receive rh-endostatin (7.5 mg/m2 once daily) on days 1 to 14 
of each 21-day cycle until tumor progression, unacceptable 
toxicity, discontinuation from study, or death.
Patients allocated to the EC group received etoposide 
(60 mg/m2) on days 1 to 5 and carboplatin at an area under the 
concentration curve of 5 mg/ml/min on day 1 of each cycle.
Study Endpoints
The primary study endpoint was assessment of PFS. The 
secondary endpoints included OS, ORR (sum of complete and 
partial remission rates), and quality of life (QOL). Tumors were 
assessed as per RECIST 1.0. Response to treatment was assessed 
every two cycles by computed tomography and confirmed at 21 
days after treatment termination. All endpoints were assessed 
by an independent review committee that included experienced 
and trained medical and oncological professionals.
Statistical Considerations
Data are presented as numbers and percentages, medians 
and ranges, or means and standard deviations (±SD). Intergroup 
comparisons were performed using Student’s t test, Wilcoxon 
rank-sum test, and Fisher’s exact test, as appropriate. Efficacy 
data are presented for the intent-to-treat patient population. 
Survival was censored at the last tumor assessment. Median 
PFS and OS were estimated by Kaplan–Meier methodology, 
and they are reported with 95% confidence intervals. Log-
rank test was used for comparison. A Cox proportional hazards 
model stratified by ECOG performance status (0–1 versus 2) 
and gender (male versus female) was used to obtain a point esti-
mate of hazard ratio (HR) for rh-endostatin plus chemotherapy 
compared with chemotherapy alone. The per protocol analysis 
included all patients who received all drugs as per study pro-
tocol, and who did not use any forbidden drugs, did not devi-
ate from study protocol, completed all assessments and did not 
withdraw from the study, except because of death. All analyses 
were conducted using SAS 9.0 (SAS Institute, Cary, NC). All 
probability tests were two-tailed, and p values less than 0.05 
were considered statistically significant.
RESULTS
Subjects’ Characteristics
Of the 140 patients enrolled, 2 withdrew consent after 
randomization; 69 patients were in the rh-endostatin + EC 
group, and 69 patients were in the EC control group. The study 
flow chart is shown in Figure 1. Table 1 depicts the baseline 
characteristics of enrolled patients.
Efficacy
Progression-free survival
Follow-up analysis of patients by August 31, 2012, 
revealed disease progression or death in 58 patients (84.1%) 
receiving rh-endostatin + EC and in 56 patients (81.2%) 
receiving EC alone. Median PFS was 6.4 months for the rh-
endostatin + EC group, and 5.9 months for the EC group 
(p = 0.213). PFS at 6 months was 59.3% in the rh-endostatin + 
EC group and 46.6% in the EC group (Fig. 2). Subgroup anal-
ysis showed that PFS in female patients (n = 25) was signifi-
cantly higher with rh-endostatin + EC (7.3 months) compared 
with EC alone (3.9 months) (p = 0.020). The corresponding 
HR in female patients was 0.4 (0.2–0.9) (Fig. 3).
Objective remission rate
The corresponding ORR (95% confidence interval) 
was 75.4% (63.5–84.9%) with rh-endostatin + EC and 66.7% 
(54.3–77.6%) with EC, but the difference was not statistically 
significant (p = 0.348). However, analysis of the per-protocol 
population showed that the ORR was significantly higher in 
patients treated with rh-endostatin + EC (86.7%; range: 75.4–
94.1%) than in the EC group (71.0%; range: 58.1–81.8%; 
p = 0.046) (Table 2).
Overall survival
Median OS among patients receiving rh-endostatin + 
EC (12.1 months) was similar to that among patients receiv-
ing EC alone (12.4 months; p = 0.812). The 1-year survival 
rate was 50.0% with rh-endostatin + EC and 54.6% with EC. 
The corresponding HR (95% confidence interval) was 1.0 
(0.7–1.5). Similar results were obtained in the per-protocol 
population (HR: 1.0 [0.7–1.6]) (Fig. 4).
Lung cancer symptom scale QOL scores
Improvements in patient-assessed QOL were signifi-
cantly greater after 4 and 6 weeks of treatment with rh-end-
ostatin + EC compared with EC (Fig. 5).
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Safety
The most common non-hematological adverse events 
(AEs) in both groups included nausea, anorexia, elevated 
alanine aminotransferase levels, elevated aspartate amino-
transferase levels, vomiting, and weakness (Table 3). In the 
rh-endostatin + EC group, one patient had elevated blood 
pressure, another had nodal tachycardia and atrial premature 
beats, and another reported palpitation. These events were all 
mild in intensity and were not reported in the EC group.
DISCUSSION
Rh-endostatin has been shown to have clinical activity 
against NSCLC.3,4 This study reports the findings of a phase 
II study comparing rh-endostatin + first-line EC chemother-
apy with EC chemotherapy alone in patients with advanced 
stage SCLC. The median PFS with rh-endostatin + EC was 
observed to be slightly longer than with EC alone, but without 
FIgURE 1.  Study flowchart and patient disposition. EC, etoposide and carboplatin; ITT, intention-to-treat. 
TAbLE 1.  Baseline Characteristics
Characteristics
rh-Endostatin 
+ EC (n = 69)
EC Alone 
(n = 69) p Value
Age (years) Mean (SD) 57.7 (8.49) 58.2 (7.84) 0.7082
Median (range) 56.0 (40–76) 59.0 (36–73)
Gender Male 56 (81.2%) 57 (82.6%) 1.0000
Female 13 (18.8%) 12 (17.4%)
ECOG 0 12 (17.4%) 13 (18.8%) 0.3187
1 52 (75.4%) 55 (79.7%)
2 5 (7.2%) 1 (1.4%)
ECOG, Eastern Cooperative Oncology Group.
FIgURE 2.  Progression-free survival (PFS) curve. EC, etopo-
side and carboplatin.
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significant difference. The results were similar to those of 
other studies of bevacizumab, paclitaxel, or irinotecan in 
combination with rh-endostatin.6–9 In as unplanned subgroup 
analysis, data suggest that Rh-endostatin + EC resulted in a 
significant PFS benefit over EC chemotherapy alone among 
female patients with SCLC. This is an interesting finding, 
since it is generally recognized that the incidence of lung can-
cer is increasing among female patients,10 but further studies 
are necessary to confirm this finding. Nevertheless, it has also 
been reported that female gender is a good prognostic factor 
for extensive-stage SCLC, and that women with both NSCLC 
and SCLC survive longer than men.10,11
In this study, there was no significant difference in OS in 
patients allocated to rh-endostatin + EC and those receiving EC 
alone. These survival rates were comparable to those observed 
with EC + bevacizumab or paclitaxel or irinotecan.1,6–9 The 
negative results observed in this study were comparable to 
the results from studies of rh-endostatin + EC in patients with 
advanced SCLC,5,12 and to the results of adding rh-endostatin 
to paclitaxel and carboplatin in NSCLC.13 Promising results 
were obtained using sunitinib maintenance therapy,14 and the 
right choice of drug combination might be essential to obtain 
positive results from rh-endostatin.
The difference of ORR between the two groups was 
not statistically significant, while another study showed an 
improved ORR in patients receiving rh-endostatin.12 However, 
when considering the per-protocol population only, ORR was 
significantly higher with rh-endostatin + EC (86.7%) than 
with EC (71.0%; p = 0.046). Nevertheless, when consider-
ing the whole population or the per protocol population, ORR 
achieved with rh-endostatin + EC was higher than that reported 
for EC + bevacizumab or irinotecan, and was comparable to 
TAbLE 2.  Remission Rates
Category
Number of Patients
p Value
rh-Endostatin + EC 
(n = 69)
EC Alone  
(n = 69)
Complete remission 2 (2.9%) 1 (1.4%)
Partial remission 50 (72.5%) 45 (65.2%)
Stable disease 5 (7.2%) 12 (17.4%)
Progressive disease 3 (4.3%) 6 (8.7%)
No assessment 9 (13.0%) 5 (7.2%)
Objective  
response rate
75.4% (63.5–84.9%) 66.7% (54.3–77.6%) 0.3483a
aFisher’s exact test. Objective response rate is the sum of the complete and partial 
remission rates.
FIgURE 4.  Overall survival (OS) curve. EC, etoposide and 
carboplatin.
FIgURE 3.  Subgroup analysis of progression-free survival curve. EC, etoposide and carboplatin; ECOG, Eastern Cooperative 
Oncology Group; HR, hazard ratio; CI, confidence interval.
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that reported for EC + irinotecan.1,6–9 Randomized studies 
should be performed to directly compare these drugs with 
rh-endostatin.
The efficacy of rh-endostatin + EC relative to that of 
EC alone was reflected by greater improvements in patient-
assessed lung cancer symptom scale QOL scores after 4 and 
6 weeks of treatment. This finding is in line with a previous 
study showing improved QOL with rh-endostatin plus carbo-
platin in the early stages of treatment of advanced NSCLC.13 
The tolerability of rh-endostatin + EC was comparable to that 
reported in another phase II study.5 No cases of severe cardio-
vascular toxicity were reported, and there were no hemato-
logical AEs. However, improvements in QOL alone, without 
improvements in OS or PFS, are not sufficient to adopt a new 
treatment. The better QOL observed in this study might be the 
result of more frequent visits to the hospital for the patients 
receiving rh-endostatin on a daily basis. However, the impact 
FIgURE 5.  Lung cancer symptom score—quality of life 
assessments. Data are expressed as median. *p < 0.05. EC, 
etoposide and carboplatin; QOL, quality of life.
TAbLE 3.  Incidence of Adverse Reactions
Adverse Reaction
All Grades, N (%)
p Value
Grades III to V, N (%)
p Value
Rh-endostatin + EC 
(n = 69)
EC Alone  
(n = 69)
Rh-endostatin + EC
( = 69)
EC Alone  
(n = 69)
Hematopoietic system
  Leukopenia 62 (89.9%) 63 (91.3%) 1.000 20 (29.0%) 15 (21.7%) 0.434
  Neutropenia 61 (88.4%) 56 (81.2%) 0.343 38 (55.1%) 27 (39.1%) 0.088
  Hemoglobin 55 (79.7%) 53 (76.8%) 0.837 11 (15.9%) 7 (10.1%) 0.449
  Thrombocytopenia 36 (52.2%) 34 (49.3%) 0.865 13 (18.8%) 13 (18.8%) 1.000
  Anemia 10 (14.5%) 4 (5.8%) 0.157 1 (1.4%) 2 (2.9%) 1.000
  Decreased absolute lymphocytes 2 (2.9%) 3 (4.3%) 1.000 1 (1.4%) 1 (1.5%) 1.000
  Decreased lymphocyte counts 0 (0%) 3 (4.3%) 0.245 0 (0%) 1 (1.5%) 1.000
  Myelosuppression 1 (1.4%) 0 (0%) 1.000 1 (1.4%) 0 (0%) 1.000
Digestive system
  Nausea 21 (30.4%) 20 (29.0%) 1.000 1 (1.4%) 0 (0%) 1.000
  Anorexia 18 (26.1%) 13 (18.8%) 0.415 1 (1.4%) 0 (0%) 1.000
  Aminopherase 16 (23.2%) 12 (17.4%) 0.526 0 (0%) 1 (1.5%) 1.000
  Vomiting 9 (13.0%) 10 (14.5%) 1.000 1 (1.4%) 0 (0%) 1.000
  Constipation 3 (4.3%) 1 (1.4%) 0.619 0 (0%) 0 (0%) N/A
  Hyperbilirubinemia 3 (4.3%) 1 (1.4%) 0.619 0 (0%) 0 (0%) N/A
  Diarrhea 1 (1.4%) 1 (1.4%) 1.000 1 (1.4%) 1 (1.5%) 1.000
  Abdominal distension 2 (2.9%) 0 (0%) 0.496 1 (1.4%) 0 (0%) 1.000
  Fecal occult blood 1 (1.4%) 0 (0%) 1.000 0 (0%) 0 (0%) N/A
General disorders
  Weakness 6 (8.7%) 5 (7.2%) 1.000 2 (2.9%) 0 (0%) 0.496
  Alopecia 6 (8.7%) 4 (5.8%) 0.745 0 (0%) 0 (0%) N/A
  Fever 1 (1.4%) 1 (1.4%) 1.000 0 (0%) 0 (0%) N/A
  Infection 1 (1.4%) 0 (0%) 1.000 0 (0%) 0 (0%) N/A
  Agranulocytic fever 1 (1.4%) 0 (0%) 1.000 0 (0%) 0 (0%) N/A
Laboratory abnormalities
  LDH 1 (1.4%) 2 (2.9%) 1.000 0 (0%) 0 (0%) N/A
  Hypocalcemia 1 (1.4%) 0 (0%) 1.000 0 (0%) 0 (0%) N/A
  Electrolyte disturbance 1 (1.4%) 0 (0%) 1.000 0 (0%) 0 (0%) N/A
LDH, lactate dehydrogenase; N/A, not applicable.
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of the 3- to 4-hour daily infusions for 14 consecutive days 
might counteract this benefit.
Despite the relatively long median follow-up of 20 
months among patients with advanced stage SCLC, the rela-
tively small sample size may have limited the power of the 
study to detect statistically significant differences between 
treatment regimens. In addition, the patients were selected 
from 14 different centers across China. While this strategy 
may make the study more applicable to a real-life setting, dif-
ferences in patient procedures between the centers may have 
influenced the study endpoints. Finally, tumor markers were 
not measured.
CONCLUSIONS
The preliminary findings in a small population of 
patients with advanced SCLC suggest that the addition of rh-
endostatin to EC for the treatment of extensive-stage SCLC 
had an acceptable toxicity profile, but did not improve OS, 
PFS, or ORR. Hence, the use of rh-endostatin in SCLC 
remains exploratory.
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